FBR Capital Remains Bullish on Seres Therapeutics (MCRB); Says Sell-Off is 'Overdone'
- Wall St. rises amid robust GDP data, mixed earnings
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
FBR Capital maintained an Outperform rating on Seres Therapeutics (NASDAQ: MCRB), and cut the price target to $23.00 (from $43.00), following the company's recent sell-off.
Analyst Vernon Bernardino commented, "We look at MCRB as the leader in advancing the microbiome approach to treating chronic diseases and infections. While we acknowledge that the near-term focus of investors may be how the primary endpoint of reducing the relative risk of infection recurrence in the SER-109 Phase II ECOSPOR clinical study in recurrent Clostridium difficile infection (CDI) was not achieved, we think the stock sell-off since July 29 is overdone. The development of MCRB’s other clinical-stage assets are partnered with Swiss-based Nestle, which has agreed to fund up to one-third of development costs, according to a $1.9B agreement signed in January 2016. MCRB has also signed four other collaborations, which we think represent nascent upside potential in the stock. Since the advancement of SER-109 may take longer than anticipated, we lower our price target from $43 per share, to $23, but we reiterate our Outperform rating."
Shares of Seres Therapeutics closed at $9.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Partners Downgrades McKesson (MCK) to Market Perform
- Oppenheimer Remains Bullish on Expedia (EXPE) Following 3Q
- Alphabet (GOOGL) (GOOG) PT Lifted to $1000 at Oppenheimer
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!